Restart Life Sciences Corp.

FRC's fair value estimate for Restart Life Sciences Corp., and the rating behind it. NMLSF last traded at $0.10; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Restart Life Sciences Corp.. Starting points for Restart Life Sciences Corp.: EPS -$0.03, beta -1.02 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Restart Life Sciences Corp.. Restart Life Sciences Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Restart Life Sciences Corp.. Trailing twelve-month EPS for Restart Life Sciences Corp. stands at -$0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Restart Life Sciences Corp.. Restart Life Sciences Corp. has reported as a listed company since 2008. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Restart Life Sciences Corp. valued side by side against its closest peers. Restart Life Sciences Corp. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Restart Life Sciences Corp., and how their positions are changing. At a $3.5M market value, institutional positions materially move Restart Life Sciences Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Restart Life Sciences Corp. executives and directors. Shares of Restart Life Sciences Corp. have traded between $0.03 and $0.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Restart Life Sciences Corp.. Restart Life Sciences Corp. is a $3.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Restart Life Sciences Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Restart Life Sciences Corp.. Coverage tracks Restart Life Sciences Corp. within Biotechnology (Healthcare). Press releases and market coverage, newest first.